Description
Tacrolimus Release Buffer
| Catalog number: | B2010730 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 25 mL |
| Molecular Weight or Concentration: | na |
| Supplied as: | Liquid |
| Applications: | tools for the research and development of CLIA assays for the detection of Tacrolimus |
| Storage: | 2-8C |
| Keywords: | Tacrolimus Extraction |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
Tacrolimus Release Buffer is a biotechnology-grade reagent formulated to facilitate the efficient extraction and release of Tacrolimus from biological matrices in chemiluminescent immunoassays (CLIA). This liquid buffer is optimized for use in assay development workflows targeting Tacrolimus, a potent immunosuppressant used in organ transplantation and autoimmune disease management. Its composition supports consistent analyte recovery from whole blood, serum, or plasma, enabling accurate quantification in high-sensitivity immunoassays. Filtered through 0.22 m membranes and prepared with ultrapure water, the buffer ensures minimal background interference and maximum assay reproducibility.
Researchers and assay developers working in therapeutic drug monitoring (TDM), transplant pharmacology, and immunoassay design rely on Tacrolimus Release Buffer to streamline sample preparation and improve assay precision. The 25 mL format provides sufficient volume for multiple extractions, and its stability at 28C supports long-term use in both manual and automated platforms. Whether you’re validating a CLIA protocol, optimizing reagent conditions, or troubleshooting Tacrolimus recovery, this buffer offers a reliable solution for enhancing assay performance and analytical sensitivity.
Key benefits:
-
Optimized for Tacrolimus extraction in CLIA-based immunoassays
-
Compatible with whole blood, serum, and plasma matrices
-
Filtered through 0.22 m membranes using ultrapure water
-
Supplied in 25 mL format for scalable assay development
-
Stable at 28C for long-term use in research workflows
Products are for in vitro research use only (RUO).
References
- Bekersky I, Fitzsimmons W, Tanase A, Maher RM, Hodosh E, Lawrence I. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis J Am Acad Dermatol. 2001 Jan;44(1 Suppl):S17-27.
- Tron C, Ferrand-Sorre MJ, Querzerho-Raguideau J, Chemouny JM, Houssel-Debry P, Verdier MC, Bellissant E, Lemaitre F. Volumetric absorptive microsampling for the quantification of tacrolimus in capillary blood by high performance liquid chromatography-tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Feb 15;1165:122521.
- Gounden V, Soldin SJ. Tacrolimus measurement: building a better immunoassay Clin Chem. 2014 Apr;60(4):575-6.
- Assmann T, Homey B, Ruzicka T. Applications of tacrolimus for the treatment of skin disorders Immunopharmacology. 2000 May;47(2-3):203-13.
- Snchez-Prez J. [Topical pimecrolimus and tacrolimus and the risk of cancer] Actas Dermosifiliogr. 2007 Jun;98(5):312-7.
- Shipley CA, Spivakovsky S. Tacrolimus or clobetasol for treatment of oral lichen planus Evid Based Dent. 2016 Mar;17(1):16.
- Wallemacq PE, Reding R. FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects Clin Chem. 1993 Nov;39(11 Pt 1):2219-28.
- Ellis D. Clinical use of tacrolimus (FK-506) in infants and children with renal transplants Pediatr Nephrol. 1995 Aug;9(4):487-94.
- McDiarmid SV. The use of tacrolimus in pediatric liver transplantation J Pediatr Gastroenterol Nutr. 1998 Jan;26(1):90-102.
